AR063601A1 - Arilamidas sustituidas por tiazol u oxazol - Google Patents

Arilamidas sustituidas por tiazol u oxazol

Info

Publication number
AR063601A1
AR063601A1 ARP070104958A ARP070104958A AR063601A1 AR 063601 A1 AR063601 A1 AR 063601A1 AR P070104958 A ARP070104958 A AR P070104958A AR P070104958 A ARP070104958 A AR P070104958A AR 063601 A1 AR063601 A1 AR 063601A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
optionally substituted
heteroaryl
hydrogen
Prior art date
Application number
ARP070104958A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR063601A1 publication Critical patent/AR063601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se proporcionan también métodos para utilizar los compuestos en el tratamiento de enfermedades, en ellas los compuestos actúan como antagonistas de receptores P2X3 y/o P2X2/3 y métodos para la obtención de los compuestos de interés. Reivindicación 1: Un compuesto de la fórmula 1, o sales farmacéuticamente aceptables del mismo, en la que: R1 es un grupo de la fórmula A o fórmula B; en las que: X es -S- u -O-; y Ra y Rb con independencia entre sí son hidrógeno; alquilo C1-6, alcoxi C1-6, alquil C1-6-sulfonil-alquilo C1-6, halo-alquilo C1-6, halo-alcoxi C1-6, hetero-alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, aminocarbonilo; alcoxi C1-6carbonilo; o ciano; o Ra y Rb junto con el átomo, al que están unidos, pueden formar un grupo fenilo, que está opcionalmente sustituido, R2 es fenilo opcionalmente sustituido; piridinilo opcionalmente sustituido; pirimidinilo opcionalmente sustituido; piridazinilo opcionalmente sustituido; o tiofenilo opcionalmente sustituido; R3 es hidrógeno; alquilo C1-6, hetero-alquilo C1-6 o ciano; R4 es hidrógeno; alquilo C1-6 o hetero-alquilo C1-6; o R3 y R4 junto con el átomo al que están unidos pueden formar un anillo carbocíclico C3-6, R5 es alquilo C1-6, hetero- alquilo C1-6, halo-alquilo C1-6, N-(alquil C1-6)amino; N,N-di-(alquil C1-6)-amino; cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6, aril-alquilo C1-6, heteroaril-alquilo C1-6, heterociclil-alquilo C1-6, heterocicliloxi; ariloxi-alquilo C1-6, -(CRcRd)rn-C(O)-R8 en el que: m es 0 o 1; Rc y Rd con independencia entre sí son hidrógeno; o alquilo C1-6, y R8 es hidrógeno; alquilo C1-6 hetero-alquilo C1-6 cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6; aril-alquilo C1-6; heteroaril-alquilo C1-6; heterociclil-alquilo C1-6; cicloalquiloxi C3-7; ariloxi; heteroariloxi; heterocicliloxi; cicloalquiloxi C3-7-alquilo C1-6; ariloxi-alquilo C1-6; heteroariloxi- alquilo C1-6, heterocicliloxi-alquilo C1-6; o -NR9R10, en el que; R9 es hidrógeno; o alquilo C1-6 y R10 es hidrógeno; alquilo C1-6, hetero-alquilo C1-6; cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6, aril- alquilo C1-6, heteroaril-alquilo C1-6 o heterociclil-alquilo C1-6, o R4 y R5 junto con el átomo al que están unidos forman un anillo carbocíclico C3-6, que está opcionalmente sustituido por hidroxi; o R4 y R5 junto con el átomo al que están unidos forman un anillo heterocíclico C4-6 que contienen uno o dos heteroátomos elegidos con independencia entre sí entre O, N y S; o R3, R4 y R5 junto con el átomo al que están unidos forman un heteroarilo de seis eslabones que tiene uno dos átomos de N y que está opcionalmente sustituido por halógeno, amino o alquilo C1-6; R6 es alq1uilo C1-6, alquiloxi C1-6; halógeno; haloalquilo C1-6, halo-alcoxi C1-6, o ciano.
ARP070104958A 2006-11-09 2007-11-07 Arilamidas sustituidas por tiazol u oxazol AR063601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85828306P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
AR063601A1 true AR063601A1 (es) 2009-02-04

Family

ID=39149180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104958A AR063601A1 (es) 2006-11-09 2007-11-07 Arilamidas sustituidas por tiazol u oxazol

Country Status (17)

Country Link
US (1) US7786110B2 (es)
EP (1) EP2091927B1 (es)
JP (1) JP5084839B2 (es)
KR (2) KR101165936B1 (es)
CN (1) CN101528717B (es)
AR (1) AR063601A1 (es)
AT (1) ATE517097T1 (es)
AU (1) AU2007316681B2 (es)
BR (1) BRPI0718714B8 (es)
CA (1) CA2668399C (es)
CL (1) CL2007003192A1 (es)
ES (1) ES2367455T3 (es)
IL (1) IL198301A (es)
MX (1) MX2009004900A (es)
PE (1) PE20081475A1 (es)
TW (1) TW200829584A (es)
WO (1) WO2008055840A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
KR101165936B1 (ko) 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
US8461185B2 (en) 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
WO2009077365A1 (en) * 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides
CA2708228C (en) * 2007-12-17 2016-06-21 F. Hoffmann-La Roche Ag Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
SI2234976T1 (sl) * 2007-12-17 2013-07-31 F. Hoffmann-La Roche Ag Novi s pirazolom substituirani arilamidi
KR101405746B1 (ko) * 2007-12-17 2014-06-10 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
CA2737038A1 (en) 2008-09-18 2010-03-25 Evotec Ag Amide compounds, compositions and uses thereof
WO2010069794A1 (en) * 2008-12-16 2010-06-24 F. Hoffmann-La Roche Ag Thiadiazole-substituted arylamides
CA2764956A1 (en) 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel biphenyl and phenyl-pyridine amides
JP5465782B2 (ja) * 2009-06-22 2014-04-09 エフ．ホフマン−ラ ロシュ アーゲー 新規オキサゾロン及びピロリジノン置換アリールアミド
NZ604035A (en) * 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2014086746A1 (de) * 2012-12-07 2014-06-12 Bayer Cropscience Ag N-(isoxazol-3-yl)-arylcarbonsäureamide und ihre verwendung als herbizide
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
KR20230098368A (ko) 2014-12-09 2023-07-03 바이엘 악티엔게젤샤프트 1,3-티아졸-2-일 치환된 벤즈아미드
KR20160138877A (ko) 2015-05-26 2016-12-06 (주)펠리테크 마이크로파를 이용한 세라믹 발열 하이브리드 건조기
MX2019003026A (es) 2016-09-15 2019-07-01 Boehringer Ingelheim Int Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
WO2020002090A1 (de) 2018-06-25 2020-01-02 Bayer Aktiengesellschaft Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe
EP3757103A1 (en) * 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN115884970A (zh) * 2020-09-24 2023-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010000178A1 (en) 1999-03-25 2001-04-05 Yu Dingwei Tim Pyridyl substituted thiazoles
AU773892B2 (en) 1999-06-30 2004-06-10 H. Lundbeck A/S Selective NPY (Y5) antagonists
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20030036189A (ko) 2000-05-26 2003-05-09 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
AU2002359376B2 (en) * 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
JP2005533777A (ja) 2002-06-17 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ抗ウイルス剤としての炭素環ヌクレオシドアナログ
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
DE14169110T1 (de) 2002-06-28 2022-05-12 Centre National De La Recherche Scientifique -Cnrs- Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084890A1 (en) 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
EP1618099A4 (en) 2003-04-18 2008-07-16 Merck & Co Inc BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS
ES2396565T3 (es) * 2003-05-12 2013-02-22 Pah Usa 15 Llc Inhibidores benzamida del receptor P2X7
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
BRPI0508461B8 (pt) * 2004-03-05 2021-05-25 Hoffmann La Roche diaminopirimidinas, seus usos, e composição farmacêutica
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
CN103159692B (zh) * 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 四唑取代的芳基酰胺类
KR101165936B1 (ko) 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
WO2009058298A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
EP2091927B1 (en) 2011-07-20
CN101528717A (zh) 2009-09-09
EP2091927A1 (en) 2009-08-26
KR101165936B1 (ko) 2012-07-19
CA2668399A1 (en) 2008-05-15
JP2010509264A (ja) 2010-03-25
IL198301A0 (en) 2010-02-17
BRPI0718714B8 (pt) 2021-05-25
KR20090086073A (ko) 2009-08-10
KR101152714B1 (ko) 2012-06-18
AU2007316681A1 (en) 2008-05-15
JP5084839B2 (ja) 2012-11-28
BRPI0718714A2 (pt) 2013-11-26
PE20081475A1 (es) 2008-10-18
IL198301A (en) 2013-06-27
ATE517097T1 (de) 2011-08-15
TW200829584A (en) 2008-07-16
AU2007316681B2 (en) 2013-01-24
KR20120034766A (ko) 2012-04-12
WO2008055840A1 (en) 2008-05-15
US7786110B2 (en) 2010-08-31
CL2007003192A1 (es) 2008-06-20
US20080132494A1 (en) 2008-06-05
BRPI0718714B1 (pt) 2020-09-29
CA2668399C (en) 2015-01-27
MX2009004900A (es) 2009-05-19
ES2367455T3 (es) 2011-11-03
CN101528717B (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR061667A1 (es) Arilamidas sustituidas con tetrazol
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
ES2515194T3 (es) Derivados de pirrolidina
ES2543567T3 (es) Métodos de utilización de inhibidores de ALK
AR073136A1 (es) Compuestos de pirrol
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR061844A1 (es) Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR078463A1 (es) Composicion y metodo para controlar plagas de artropodos
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR054529A1 (es) Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR076401A1 (es) Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)
AR066603A1 (es) Derivados de arilamida pirimidona

Legal Events

Date Code Title Description
FB Suspension of granting procedure